Clinical experience with gefitinib: an update

Critical Reviews in Oncology/hematology
Federico CappuzzoLucio Crino

Abstract

Gefitinib is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways involved in cell proliferation. This drug demonstrated impressive and durable responses in patients with heavily pretreated non-small cell lung cancer (NSCLC). In two large phase II trials, responses were observed in 9-19% of unselected patients, along with symptom improvement and benefit in quality of life. Biological mechanisms underlying TKI sensitivity have recently been discovered. There is evidence that specific EGFR gene mutations and/or amplification confer a particularly sensitive phenotype, especially in individuals with tumors demonstrating activation of the anti-apoptotic protein Akt. However, in all so far conducted clinical trials, no patient selection has been made, providing a logical explanation for the negative results observed in large phase III studies. In the present review, we will summarize the results observed in clinical trials with gefitinib. We will present results obtained in NSCLC and in other solid tumor, focusing on biological and clinical markers predicting drug sensitivity.

Citations

Dec 17, 2008·Molecular Cancer Therapeutics·Elaine T LamLia Gore
Aug 10, 2007·Breast Cancer Research : BCR·Iain R HutchesonRobert I Nicholson
Nov 15, 2006·Annals of Surgical Oncology·Neeltje SteeghsHans Gelderblom
Jun 11, 2009·International Journal of Oncology·Richard E FrancisEric W-F Lam
May 19, 2006·Expert Opinion on Biological Therapy·Sabrina OliveiraRaymond M Schiffelers
Jan 1, 2009·Expert Opinion on Drug Discovery·Fernanda I StaquiciniWadih Arap
Jun 14, 2008·Expert Opinion on Investigational Drugs·Patricia M Lorusso, Joseph Paul Eder
Jan 16, 2010·Cancer Investigation·Apar Kishor Ganti
Apr 26, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Federico Cappuzzo
Jun 29, 2010·Cancer Science·Shun'ichiro TaniguchiJun Amano
Jun 4, 2011·Expert Opinion on Therapeutic Patents·Margrith E MattmannCraig W Lindsley
Apr 27, 2011·Laboratory Investigation; a Journal of Technical Methods and Pathology·Yalai BaiAnnette M Molinaro
Mar 7, 2007·Clinical Pharmacology and Therapeutics·K McLarty, R M Reilly
Apr 13, 2019·Journal of Experimental & Clinical Cancer Research : CR·N A SeebacherA M Merlot
Mar 12, 2009·Molecular Cancer Therapeutics·Ursula B McGovernEric W-F Lam
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Iduna FichtnerJohannes Merk
Aug 6, 2008·Journal of Medicinal Chemistry·Alejandro CrespoAriel Fernández

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.